Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019063829) IMMUNOGENIC COMPOSITION FOR THE TREATMENT OF CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/063829 International Application No.: PCT/EP2018/076539
Publication Date: 04.04.2019 International Filing Date: 28.09.2018
IPC:
A61K 39/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
Applicants:
MELIEF, Jeroen [NL/SE]; SE
KIESSLING, Rolf Valter Rikard [SE/SE]; SE
Inventors:
MELIEF, Jeroen; SE
KIESSLING, Rolf Valter Rikard; SE
Agent:
DIDMON, MARK; Potter Clarkson LLP, The Belgrave Centre Talbot Street Nottingham Nottinghamshire NG1 5GG, GB
Priority Data:
17194223.829.09.2017EP
Title (EN) IMMUNOGENIC COMPOSITION FOR THE TREATMENT OF CANCER
(FR) COMPOSITION IMMUNOGÉNIQUE POUR LE TRAITEMENT DU CANCER
Abstract:
(EN) The invention relates to the field of immunotherapy, more in particular to a composition for use in the treatment of cancer. The invention also relates to a composition obtainable by such a method, such as a pharmaceutical composition. More in particular, the invention relates to an ex vivo method for obtaining a composition suitable for the treatment of cancer in a subject, comprising the steps of providing primary tumor cells derived from the subject, and ex vivo contacting the tumor cells with an inhibitor of a bromodomain and extra-terminal domain family member (BET inhibitor).
(FR) La présente invention concerne le domaine de l'immunothérapie, en particulier une composition destinée à être utilisée dans le traitement du cancer. L'invention concerne également une composition pouvant être obtenue par un tel procédé, telle qu'une composition pharmaceutique. Plus particulièrement, l'invention concerne un procédé ex vivo pour obtenir une composition appropriée pour le traitement du cancer chez un sujet, comprenant les étapes consistant à fournir des cellules tumorales primaires dérivées du sujet, et à mettre en contact ex vivo les cellules tumorales avec un inhibiteur d'un membre de la famille bromodomaine et domaine extraterminal (inhibiteur BET).
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)